<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01302444</url>
  </required_header>
  <id_info>
    <org_study_id>T2 Trial</org_study_id>
    <nct_id>NCT01302444</nct_id>
  </id_info>
  <brief_title>Treprostinil Combined With Tadalafil for Pulmonary Hypertension</brief_title>
  <acronym>T2</acronym>
  <official_title>Randomized Placebo Controlled Trial of Treprostinil Infusion Combined With Oral Tadalafil or Placebo in Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rhode Island Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: To test whether the combined administration of the medications treprostinil(a
      prostacycline therapy), and tadalafil(a PDE-5 [ phosphodiesterase type 5]Inhibitor therapy)
      is better than the administration of treprostinil alone. This treatment would be offered to
      newly diagnosed patients with pulmonary arterial hypertension who are on no treatment for
      this disease and are deemed candidates for the medication treprostinil by their physician.
      The combination therapy will be compared to single therapy with only treprostinil in a
      double-blind manner.

      Current therapy is to begin one treatment, either a PDE5 inhibitor or a prostacycline,
      depending on the severity of the patient's PAH (pulmonary arterial hypertension) disease and
      add additional therapies as deterioration occurs. This treatment could add two agents
      initially.

      Secondary objectives are: To improve pulmonary arterial pressures as measured through a
      cardiac echocardiogram, improve the subject's 6minute walk distance, delaying the time to
      clinical worsening, and lowering plasma BNP levels.

      Research Procedures: To begin the administration of both treatments at the same time.

      Time period is 16 weeks with a one- year follow-up. Cardiac Echocardiograms, clinic physician
      exams, and lab work will be followed. Subjects will be between the ages of 18 - 75.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Many cardiovascular diseases such as essential hypertension, coronary artery
      disease and congestive heart failure respond better to combinations of vasoactive drugs, than
      to therapy with a single agent. Three categories of pulmonary anti-hypertensive medications
      have been developed over the last 20 years, but their effect on management of PAH when used
      in combination are mostly unknown. Two of the pulmonary arterial hypertension (PAH) drug
      groups are prostacyclines, and PDE5 inhibitors. Although the effects of prostacyclins are
      mediated via cAMP (cyclic guanosine monophosphate) and the effects of PDE5 inhibitors are
      mediated via cGMP, there is considerable cross talk between these nucleotides suggesting that
      adequate levels of both may be needed to maintain normal pulmonary vascular tone and cellular
      growth responses.

      Objective/Hypothesis: This proposal hypothesizes that increasing the levels of both
      nucleotides (prostacyclines and PDE5 inhibitors), may be more efficacious in the treatment of
      PAH than increasing either one alone.

      Specific Aims: The primary objective of this study is to determine if the combination of
      treprostinil infusion combined with tadalafil is more efficacious than treprostinil alone in
      improving the change from baseline in the 6 minute walking distance after 16 weeks of
      therapy.

      Study Design: The proposed study is a multi-center, randomized, double blind, two cohort,
      parallel group, and 16-week study with 1-year long-term follow-up. The study aims to compare
      the efficacy of combination therapy with treprostinil infusion and tadalafil to treprostinil
      infusion alone.

      Study Population: All patients who have been newly diagnosed with PAH and who, after
      consultation with their physician, have elected to be treated with treprostinil infusion will
      be invited to participate. A total of 66 subjects will be sort to enroll.

      Treprostinil dosing will follow a 4 week up-titration schedule with a target 4week dose of
      8ng/kg/min minimum, followed by a 12 week randomized tadalafil period.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    One subject enrolled and completed this study. The study was stopped due to poor recruitment.
  </why_stopped>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events Are no Greater Than With Treprostinil Infusion Alone</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>WHO Functional Class Will Improve or Remain Stable</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walking Distance Change Will Improve</measure>
    <time_frame>16 weeks of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tei Index Change by Transthoracic Echocardiography</measure>
    <time_frame>16 weeks of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma BNP (Brain Natriuretic Peptide)Level Change</measure>
    <time_frame>16 weeks of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulmonary Arterial Systolic Pressure (PASP)as Assessed by Transthoracic Echocardiography Using Doppler Ultrasound</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Tadalafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Tadalafil 40mg for 12 weeks</description>
    <arm_group_label>Tadalafil</arm_group_label>
    <other_name>Adcirca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients 18-80 years of age

          2. World Health Organization Group 1 PAH

               1. Idiopathic PAH

               2. Heritable PAH

               3. PAH associated with connective tissue disease

               4. PAH associated with surgical repair of congenital left to right shunt

               5. PAH associated with anorectic drug use

          3. WHO functional Class III-IV

          4. 6 minute walking distance &gt; 150-meters and &lt; 450 meters

          5. Right heart catheterization showing mean PAP (pulmonary arterial pressure)&gt; 25 mmHg
             and PCWP (pulmonary capillary wedge pressure) &lt; 15 mmHg within 6 months of study
             entry.

        Exclusion Criteria:

          1. Pulmonary hypertension associated with

             a. Portal hypertension b. HIV infection c. Pulmonary venous hypertension defined as
             PCWP &gt; 15 mmHg d. Chronic lung disease defined as i. FEV1(forced expiratory volume at
             one second

             )/FVC (forced vital capacity) less than 0.65 ii. TLC &lt; 0.70 iii. Untreated Sleep Apnea
             with AHI (apnea-hypopnea index )&gt; 20 or hemoglobin oxygen saturation nadir &lt; 87% e.
             Chronic Thromboembolic Disease f. Sarcoidosis g. Pulmonary veno occlusive disease
             (PVOD)

          2. Concomitant use of nitrates (any form) either regularly or intermittently.

          3. Concomitant use of potent CYP3A inhibitors (e.g., ritonavir, ketoconazole,
             itraconazole)

          4. Vascular disease of the retina including retinitis pigmentosa, any sudden vision loss,
             including any damage to the optic nerve or NAION

          5. low blood pressure or high blood pressure that is not controlled

          6. Postural hypotension

          7. Inability to manage home infusion therapy

          8. Pulmonary vasodilator therapy with any phosphodiesterase inhibitor or endothelin
             receptor antagonist within 30 days of study entry

          9. Participation in a clinical investigational study within previous 30 days

         10. Renal failure defined as:

               1. estimated creatinine clearance &lt; 30 ml/min

               2. serum creatinine &gt; 2.5 mg/dl

         11. Subjects with liver function abnormalities (ALT [Alanine Aminotransferase or AST
             (Alanine Aminotransferase ) &gt; 3 times the upper limit of normal at screening or at
             baseline) or chronic liver disease

         12. History of hypersensitivity reaction or adverse effect related to tadalafil

         13. Life expectancy &lt; 12 months

         14. History of deformed penis shape, an erection that lasted more than 4 hours, or
             Peyronie's disease.

         15. Blood cell problems such as sickle cell anemia, multiple myeloma, or leukemia

         16. Pregnant or planning to become pregnant or breast feed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James R Klinger, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rhode Island Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tuft's New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Barnabas Health Care System, Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>new York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515411/</url>
    <description>treprostinil</description>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <results_first_submitted>June 7, 2013</results_first_submitted>
  <results_first_submitted_qc>June 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 18, 2013</results_first_posted>
  <last_update_submitted>July 18, 2013</last_update_submitted>
  <last_update_submitted_qc>July 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treprostinil</keyword>
  <keyword>pulmonary hypertension, tadalafil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Treprostinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tadalafil</title>
          <description>first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tadalafil</title>
          <description>first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>All Cause Mortality</title>
        <time_frame>16 weeks</time_frame>
        <population>data not reported for one participant for anonymity</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <population>data not reported for one participant for anonymity</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events Are no Greater Than With Treprostinil Infusion Alone</title>
        <time_frame>16 weeks</time_frame>
        <population>data not reported for one participant for anonymity</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events Are no Greater Than With Treprostinil Infusion Alone</title>
          <population>data not reported for one participant for anonymity</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>WHO Functional Class Will Improve or Remain Stable</title>
        <time_frame>16 weeks</time_frame>
        <population>data not reported for one participant for anonymity</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>WHO Functional Class Will Improve or Remain Stable</title>
          <population>data not reported for one participant for anonymity</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hospitalizations</title>
        <time_frame>16 weeks</time_frame>
        <population>data not reported for one participant for anonymity</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalizations</title>
          <population>data not reported for one participant for anonymity</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6 Minute Walking Distance Change Will Improve</title>
        <time_frame>16 weeks of therapy</time_frame>
        <population>data not reported for one participant for anonymity</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>6 Minute Walking Distance Change Will Improve</title>
          <population>data not reported for one participant for anonymity</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tei Index Change by Transthoracic Echocardiography</title>
        <time_frame>16 weeks of therapy</time_frame>
        <population>data not reported for one participant for anonymity</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Tei Index Change by Transthoracic Echocardiography</title>
          <population>data not reported for one participant for anonymity</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma BNP (Brain Natriuretic Peptide)Level Change</title>
        <time_frame>16 weeks of therapy</time_frame>
        <population>data not reported for one participant for anonymity</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma BNP (Brain Natriuretic Peptide)Level Change</title>
          <population>data not reported for one participant for anonymity</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulmonary Arterial Systolic Pressure (PASP)as Assessed by Transthoracic Echocardiography Using Doppler Ultrasound</title>
        <time_frame>16 weeks</time_frame>
        <population>data not reported for one participant for anonymity</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulmonary Arterial Systolic Pressure (PASP)as Assessed by Transthoracic Echocardiography Using Doppler Ultrasound</title>
          <population>data not reported for one participant for anonymity</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tadalafil</title>
          <description>first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James R Klinger, MD</name_or_title>
      <organization>Rhode Island Hospital</organization>
      <email>jklinger@lifespan.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

